BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Money on the Move: December 8 – 14

  During a season of giving, investors were extra generous to these biotech companies this week.

  December 15, 2021

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Biotech Bay

  J.P. Morgan Goes Virtual as Key Companies Back Out

  Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.

  December 15, 2021

   · 

  5 min read

   · 

  Gail Dutton
• 

  FDA

  FDA Warns Medtronic About Inadequacies at Diabetes Device Facility

  The latest warning letter asks Medtronic to update its systems and procedures in order to deliver safe and high-quality devices to consumers.

  December 15, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Sanofi/GSK Booster Shot Looking Good But Delayed Until 2022

  Sanofi and GlaxoSmithKline reported that their potential COVID-19 booster shot delivered good immune response in its preliminary clinical trials.

  December 15, 2021

   · 

  2 min read

   · 

  Alvin Clavines
• 

  Deals

  BeiGene’s Triple Listing Bears Brunt of Escalating U.S.-China Tensions

  Shares of BeiGene have fallen 16% in China in part due to concerns over potential U.S. sanctions against Chinese biotech companies.

  December 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Global Roundup: Aussie Biopharma Raises $25 Million to Expand in US

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  December 15, 2021

   · 

  7 min read

   · 

  Alex Keown
• 

  Drug Development

  Pfizer’s JAK Inhibitor Xeljanz Racks Up Another FDA Win

  The FDA’s approval of Xeljanz is based on Pfizer’s Phase III multicenter, double-blind, placebo-controlled study. Here are more details about the study.

  December 15, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Lilly UC Treatment Holds Edge in Maintenance Study, Setting Up BLA

  These results set Lilly up well to submit a Biologics License Application (BLA) in the first half of 2022.

  December 15, 2021

   · 

  3 min read

   · 

  Sreetama Dutt
• 

  Drug Development

  Notch Another Win for AbbVie’s Rinvoq, This Time in Psoriatic Arthritis

  The FDA approved the latest indication for Rinvoq (upadacitinib) based on data from two Phase III studies, SELECT-PsA 1 and SELECT-PsA 2.

  December 15, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Genetown

  Mythic Therapeutics Scores $103 Million to Make “Safer and Smarter” ADCs

  Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).

  December 15, 2021

   · 

  3 min read

   · 

  Alex Keown